BeiGene - ONC Enterprise Value-to-Revenue Multiple

Official company branding of BeiGene (ONC)

BeiGene Ltd is a biotechnology player facing severe pricing pressure from China and geopolitical tensions. The enterprise value-to-revenue ratio, illustrated by this chart from the GURU.Markets system, highlights the impact of these risks, where the value 5780.38 serves as the baseline indicator. BeiGene Ltd is reducing its dependence on China through the global export of its drugs. Innovations are based on targeted therapy that minimizes treatment toxicity.

ONC: BeiGene EV/Sales Multiple 11/23/2025 - 11/20/2026

ONC (BeiGene Corp): analytical breakdowns and indicator data

- stock value and consensus price forecast:
Fundamental valuation:BeiGene Ltd (ONC)
Product sample of BeiGene Ltd.

Investors must identify an objective entry point based on the intrinsic value of BeiGene Ltd assets. The presence of high-tech manufacturing plants in the US and China ensures stable drug production, establishing revenue as a reliable basis for valuation. Analyzing the enterprise value-to-revenue chart allows for a business assessment independent of debt load, defining fair price corridors to minimize the risk of overpayment.

Competitor analysis for BeiGene Ltd

HALO: Enterprise Value-to-Revenue Ratio|Revolution Medicines Corp (RVMD) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Ascentage Pharma Group International (AAPG)|Enterprise Value-to-Revenue Ratio CG Oncology, Inc.|Enterprise Value-to-Revenue Multiple UroGen Pharma Corp URGN|EV/Sales Multiple BCAX|Personalis, Inc. - Company Value to Revenue Ratio|Erasca - Company Value to Revenue|Business Value to Revenue DCTH|YMAB: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Aura Corp|CADL: EV/Sales Multiple|ARAY - Total Company Value-to-Revenue Ratio|SLS (SELLAS Life Sciences Group, Inc.) - EV/Sales Multiple|ACTU: Business Value to Revenue|Enterprise Value-to-Revenue Ratio citiusonc.com (CTOR)|Total Company Value-to-Revenue Ratio TuHURA Biosciences|Enterprise Value-to-Revenue Ratio Protara Therapeutics TARA|Fate Therapeutics (FATE) - Enterprise Value-to-Revenue Multiple|WHWK - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple TScan Therapeutics Inc|championsoncology.com (CSBR) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio XBIT|Company Value to Revenue CVM|Company Value to Revenue Ratio OSTX (OS Therapies Incorporated)|EV/Sales Multiple RADX|ARTV: Enterprise Value to Sales Volume|EV/Sales Multiple ANL (Adlai Nortye Ltd)|VERU - Company Value to Revenue|tempesttx.com - EV/Sales Multiple|Business Value to Revenue XLO (xiliotx.com)|RENB: EV/Sales Multiple|Company Value to Revenue Mural Oncology plc|Enterprise Value-to-Revenue Ratio Kairos Pharma Inc|OKUR: Business Value to Revenue|EV/Sales Multiple GDTC|CRIS (Curis) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio apollomicsinc.com APLM|THAR: Company Value to Revenue Ratio|advanbiomed.com - EV/Sales Multiple|Business Value to Revenue GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Enterprise Value-to-Revenue Ratio|Sunshine Biopharma Inc. (SBFM) - EV/Sales Multiple|XBIO (Xenetic Bio) - EV/Sales Multiple|Salarius Pharmaceuticals Inc (SLRX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PPBT|EV/Sales Multiple American Oncology Network Inc (AONC)|EV/Sales Multiple BGNE (BeiGene Ltd.)|Enterprise Value-to-Revenue Coefficient CKPT (Checkpoint Therapeutics)|ELEV - Enterprise Value-to-Revenue Ratio|ICAD (iCAD Inc.) - Company Value to Revenue Ratio|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio